hypertrophic cardiomyopathy
BMS builds case for mavacamten label ahead of FDA decision
Phil Taylor
Bristol-Myers Squibb, cardiology, hypertrophic cardiomyopathy, mavacamten
0 Comment
X
BMS builds case for mavacamten label ahead of FDA decision
https://pharmaphorum.com/news/bms-builds-case-for-mavacamten-label-ahead-of-fda-decision/
Look out BMS, Cytokinetics has its eye on mavacamten’s turf
Phil Taylor
Bristol-Myers Squibb, cardiology, Cytokinetics, hypertrophic cardiomyopathy, mavacamten, Myokardia
0 Comment
X
Look out BMS, Cytokinetics has its eye on mavacamten’s turf
https://pharmaphorum.com/news/look-out-bms-cytokinetics-has-its-eye-on-mavacamtens-turf/